---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-052112"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2026-08-04T10:31:28+00:00"
generated_at: "2026-08-04T10:35:25.016046+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InfuSystem Q2 net revenue $36.9M, up 2.6%; net income $3.2M; reaffirms 2026 guidance

## Summary
- Net revenues $36.9M (+2.6% YoY); Patient Services +15% to $24.8M, Device Solutions -16% to $12.1M.
- Net income $3.2M ($0.15 diluted EPS) vs $2.6M ($0.12) prior year; Adjusted EBITDA $8.6M (+7.6%), margin 23.4%.
- Reaffirmed FY 2026 guidance: pro-forma revenue growth 6-8%, Adjusted EBITDA margin mid-to-low 20s.
- Stock repurchases $3.5M in Q2; liquidity $55.2M as of June 30, 2026.
- GE Healthcare contract restructuring cut Device Solutions revenue $1.6M but improved profitability and margins.

## SEC filing metadata
- accession: 0001628280-26-052112
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2026-08-04T10:31:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828026052112/0001628280-26-052112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828026052112/infu-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-052112
- JSON: https://secwatch.observer/filing/0001628280-26-052112.json
- Plain text: https://secwatch.observer/filing/0001628280-26-052112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.